Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Saccharin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saccharin SCHEMBL1138065 | 1.00 | GPR3 (0.43) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL29364573 | 1.00 | GPR3 (0.43) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL3372 | 0.98 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL29355014 | 0.98 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL787894 | 0.98 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL10399957 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL473608 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL2954783 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL10618576 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 | |
| Saccharin SCHEMBL5870938 | 0.94 | GPR3 (0.44) | GPR3CA9CA12KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636289-B2 | Lamotrigine oral liquid suspension and use thereof | OWP Pharmaceuticals, Inc. (US) | 2026-05-26 | — | — | US | claimed |
| EP-4731180-A1 | A POWDER COMPOSITION FOR ORAL SUSPENSION OF PROTON PUMP INHIBITORS AND THE METHOD OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-04-29 | — | — | EP | claimed |
| EP-3523274-B1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | ORBUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4575496-A2 | METHOD OF ASSESSING GROWTH HORMONE DEFICIENCY IN HUMANS BY A MACIMORELIN CONTAINING COMPOSITION | Aeterna Zentaris GmbH (DE) | 2025-06-25 | — | — | EP | claimed |
| WO-2024261481-A1 | A POWDER COMPOSITION FOR ORAL SUSPENSION OF PROTON PUMP INHIBITORS AND THE METHOD OF PREPARING THE SAME | ORBIT PHARMA LIMITED (GB) | 2024-12-26 | — | — | WO | claimed |
| CN-114727955-B | Preparation containing lipid-lowering and blood pressure-lowering drugs | 福多兹制药公司 | 2024-03-26 | — | — | CN | claimed |
| US-20240082259-A1 | QUETIAPINE ORAL LIQUID SUSPENSION AND USE THEREOF | OWP PHARMACEUTICALS INC (US) | 2024-03-14 | — | — | US | claimed |
| CN-111684283-B | Method for assessing human growth hormone deficiency by a composition comprising moxirelin | 阿特纳赞塔里斯有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-117530943-A | Formulations for administration of efluromithine | 奥巴斯治疗股份有限公司 | 2024-02-09 | — | — | CN | claimed |
| US-11872309-B2 | Topiramate oral liquid suspension and use thereof | OWP Pharmaceuticals, Inc. | 2024-01-16 | — | — | US | claimed |
| EP-2683358-A1 | MICRONEEDLE DEVICES AND METHODS | 3M Innovative Properties Company (US) | 2014-01-15 | — | — | EP | claimed |
| US-20120328537-A1 | Topical wound management formulation | STENGER, JAMES P. | 2012-12-27 | — | — | US | claimed |
| WO-2012122162-A1 | MICRONEEDLE DEVICES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-13 | — | — | WO | claimed |
| US-20090047473-A1 | NI-CONTAINING PLATING FILM AND METHOD OF MANUFACTURING THE SAME | ALPS ELECTRIC CO., LTD. (JP) | 2009-02-19 | — | — | US | claimed |
| EP-1237539-B1 | ORAL SOLUTION CONTAINING GALANTHAMINE AND A SWEETENING AGENT | JANSSEN PHARMACEUTICA NV (BE) | 2005-10-19 | — | — | EP | claimed |
| CN-1200691-C | Oral liquid containing galanthamine and sweetener | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | CN | claimed |
| US-20050063998-A1 | Oral solution containing galantamine and a sweetening agent | FRANCOIS MARC KAREL JOZEF (BE) | 2005-03-24 | — | — | US | claimed |
| CN-1382037-A | Oral solution containing galanthamine and sweetening agent | JANSSEN PHARMACEUTICA NV (BE) | 2002-11-27 | — | — | CN | claimed |
| EP-0670725-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN GASTROINTESTINAL WASHES | BLOCK DRUG COMPANY, INC. (US) | 1995-09-13 | — | — | EP | claimed |
| WO-1994012191-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN GASTROINTESTINAL WASHES | BLOCK DRUG COMPANY, INC. (US) | 1994-06-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636289-B2 | Lamotrigine oral liquid suspension and use thereof | SORD, SDHA, RPL27A | MEN1 2071/4885GPR3 2804/4885CA9 3955/4885 |
| US-20050063998-A1 | Oral solution containing galantamine and a sweetening agent | GALC, GALR1, GALR2 | MEN1 1501/4885GPR3 360/4885CA9 455/4885 |
| US-20240082259-A1 | QUETIAPINE ORAL LIQUID SUSPENSION AND USE THEREOF | SLC6A4, SLC6A3, FH | MEN1 3334/4885GPR3 1067/4885CA9 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.